Global Stem Cells Group (GSCG) has announced the appointment of Dr Rafael Moguel as the new Chief Medical Officer (CMO) of Cellular Hope Institute Cancun.
Dr Moguel, Fellow of the Society for Cardiac Angiography and Intervention (SCAI), and Member of the Mexican Society for Interventional Cardiologists, and Latin American Society for Interventional Cardiology, comes with a wealth of experience and training.
As CMO with vast knowledge and experience, Dr Moguel is expected to change the direction of Cellular Hope Institute Cancun, which offers patients the best treatments for multiple conditions such as sports medicine, pediatric care, chronic degenerative disease, and autoimmunity. It’s a multi-specialty training center for cellular therapies and regenerative medicine, offering the most advanced treatments in cell therapy.
“I have full confidence in the appointment of Dr Rafael Moguel as the CMO of Cellular Hope Institute Cancun. Benito Novas, CEO of Global Stem Cells Group, has said. The CEO expressed his satisfaction in Dr Moguel’s abilities and experience, and has no doubt he (Dr Moguel) will advance the objectives of Cellular Hope Institute and propel it to new heights.
With his impressive resume, it’s easy to understand why GSCG CEO is exuding confidence in Dr Moguel’s appointment. Dr Moguel has served in various capacities across several top medical institutions. He was the assistant professor for Cardiology and Interventional Cardiology at Hospital 1° de Octubre, where he also handled hemodynamics and internal medicine.
In his acceptance speech, Dr Moguel has said: “I want to affirm and reaffirm my commitment to the goals of Cellular Hope Institute.” With his elaborate working experience and professionalism in cellular therapy, he expressed his confidence in rising to the expectations of Cellular Hope Institute.
Dr Moguel received his medical degree at Universidad Veracruzana in 1983. He holds a valid certification by the Mexican Cardiology Board for Interventional Cardiology. With more than 10,000 interventional procedures, most notably peripheral and brain intervention, coronary, pacemakers and vein interventions, Dr Moguel has all it takes to propel Cellular Hope Institute to the next level.
The appointment of Dr Moguel comes barely two months after an earlier announcement by the GSCG about the opening the multispecialty regenerative medicine center in Cancun. The facility’s main objective is to incorporate different treatments basing on regenerative medicine, and serve as a training center for cellular therapies and regenerative medicine.
Dr Moguel’s rich background as an assistant professor and head of interventional cardiology and hemodynamics positions him as the best candidate to run Cellular Hope Institute. His experience is set to make this facility one of the best cellular therapy centers worldwide, and provide more specialized treatment for patients requiring regenerative medicine.
About Cellular Hope Institute
This facility is a center for both patients and medical experts worldwide, and its main objective is to benefit medical experts and patients globally. The facility achieves this objective through offering the best treatments for patients with multiple conditions, such as spinal cord injury, chronic obstructive pulmonary, sports medicine, and autoimmunity, among others. If you need more information about Cellular Hope Institute, please contact us today.
About the Global Stem Cell Group
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website.